FDA Expecting 43% Increase In ANDA Submissions For FY 2005
Executive Summary
FDA's Office of Generic Drugs expects to receive 806 abbreviated new drug applications in fiscal year 2005, representing a 43% increase over the 563 received in FY 2004
You may also be interested in...
Generic User Fees Must Be Considered Due To Ballooning ANDAs – FDA’s Galson
The "exponential" growth of ANDA submissions necessitates an examination of user fees for generic applications, Center for Drug Evaluation & Research Director Steven Galson told the Generic Pharmaceutical Association's Fall Technical Conference Oct. 24
Generic User Fees Must Be Considered Due To Ballooning ANDAs – FDA’s Galson
The "exponential" growth of ANDA submissions necessitates an examination of user fees for generic applications, Center for Drug Evaluation & Research Director Steven Galson told the Generic Pharmaceutical Association's Fall Technical Conference Oct. 24
Able Labs To Withdraw Seven ANDAs; Data Integrity Concerns Cited
Able Labs "is no longer willing to rely" on the data in some of its approved ANDAs, the generic drug manufacturer said May 23